Literature DB >> 28679523

Global Longitudinal Strain and Left Atrial Volume Index Provide Incremental Prognostic Value in Patients With Hypertrophic Cardiomyopathy.

Yasmine L Hiemstra1, Philippe Debonnaire1, Marianne Bootsma1, Erik W van Zwet1, Victoria Delgado1, Martin J Schalij1, Douwe E Atsma1, Jeroen J Bax1, Nina Ajmone Marsan2.   

Abstract

BACKGROUND: Current methods for predicting adverse events in patients with hypertrophic cardiomyopathy are still limited. Left ventricular global longitudinal strain (GLS) and left atrial volume index (LAVI) have been recently proposed as novel prognostic factors in several cardiovascular diseases. The objective of this study was to evaluate the prognostic value of GLS and LAVI in patients with hypertrophic cardiomyopathy. METHODS AND
RESULTS: Two-dimensional echocardiography was performed in 427 patients with hypertrophic cardiomyopathy (66% men, age 52±15 years), and LAVI and GLS were assessed. During follow-up, the primary end point of all-cause mortality, heart transplantation, sudden cardiac death, and appropriate implantable cardioverter defibrillator therapy was noted. A total of 103 patients reached the primary end point during a follow-up of 6.7 (interquartile range, 3.3-10.0) years. Multivariable Cox regression analysis revealed GLS and LAVI to be independently associated with the primary end point (hazard ratio GLS, 1.10 [1.03-1.19], P=0.007; hazard ratio LAVI, 4.27 [2.35-7.74], P<0.001) after correcting for other clinical variables. When applying the pre-specified cut-off values of 34 mL/m2 for LAVI and -15% for GLS, Kaplan-Meier survival curves showed significant better survival for patients with LAVI <34 mL/m2 (P<0.001) and GLS <-15% (P<0.001) as compared with their counterparts. The likelihood ratio test showed a significant incremental prognostic value of LAVI and GLS (P<0.001) as compared with a model with clinical and standard echocardiographic risk factors. The C-statistic for this model increased from 0.68 to 0.73 when adding GLS and LAVI.
CONCLUSIONS: GLS and LAVI are independently associated with adverse outcome in patients with hypertrophic cardiomyopathy and may help to optimize risk stratification in these patients.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  cardiomyopathy, hypertrophic; death, sudden, cardiac; ehocardiography; heart transplantation; prognosis

Mesh:

Year:  2017        PMID: 28679523     DOI: 10.1161/CIRCIMAGING.116.005706

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  14 in total

1.  Multimodality imaging: Bird's eye view from The European Society of Cardiology Congress 2016 : Rome, August 27-31, 2016.

Authors:  Jeroen J Bax; Victoria Delgado; Stephan Achenbach; Sven Plein; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2017-02       Impact factor: 5.952

2.  Global myocardial longitudinal strain in a general population-associations with blood pressure and subclinical heart failure: The Tromsø Study.

Authors:  Michael Stylidis; David A Leon; Assami Rӧsner; Henrik Schirmer
Journal:  Int J Cardiovasc Imaging       Date:  2019-12-18       Impact factor: 2.357

3.  The value of myocardial work in assessment of ventricular function in patients with non-obstructive hypertrophic cardiomyopathy.

Authors:  Chenguang Yang; Ying Guo; Xiang Wang; Ruisheng Zhang; Fang Wang; Huolan Zhu
Journal:  BMC Cardiovasc Disord       Date:  2022-07-05       Impact factor: 2.174

4.  Left Ventricular Myocardial Remodeling and Prognostic Marker Derived from Postmyectomy Cardiac MRI Feature Tracking in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Shujuan Yang; Keshan Ji; Xiuyu Chen; Fei Li; Kai Yang; Shiqin Yu; Yucong Zheng; Yanyan Song; Kankan Zhao; Minjie Lu; Shengwei Wang; Shuiyun Wang; Shihua Zhao
Journal:  Radiol Cardiothorac Imaging       Date:  2022-03-24

Review 5.  Contemporary narrative review on left atrial strain mechanics in echocardiography: cardiomyopathy, valvular heart disease and beyond.

Authors:  Vardhmaan Jain; Raktim Ghosh; Manasvi Gupta; Yoshihito Saijo; Agam Bansal; Medhat Farwati; Rachel Marcus; Allan Klein; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

6.  Characterization of hypertrophic cardiomyopathy according to global, regional, and multi-layer longitudinal strain analysis, and prediction of sudden cardiac death.

Authors:  Marie-Philippe Vergé; Hubert Cochet; Amélie Reynaud; Lucas Morlon; Jérôme Peyrou; Cécile Vincent; Caroline Rooryck; Philippe Ritter; Stéphane Lafitte; Patricia Réant
Journal:  Int J Cardiovasc Imaging       Date:  2018-02-27       Impact factor: 2.357

Review 7.  Multimodality imaging predictors of sudden cardiac death.

Authors:  Fancesco Bandera; Lilit Baghdasaryan; Giulia Elena Mandoli; Matteo Cameli
Journal:  Heart Fail Rev       Date:  2020-05       Impact factor: 4.214

8.  Strain Analysis of Left Ventricular Function in the Association of Hypertrophic Cardiomyopathy and Systemic Arterial Hypertension.

Authors:  Thereza Cristina Pereira Gil; Marcia Bueno Castier; Alyne Freitas Pereira Gondar; Ana Ferreira Sales; Marceli de Oliveira Santos; Fernanda Cristina da Silva de Lima; Ricardo Mourilhe-Rocha
Journal:  Arq Bras Cardiol       Date:  2019-09-02       Impact factor: 2.000

9.  Hemodynamic determinants of left atrial strain in patients with hypertrophic cardiomyopathy: A combined echocardiography and CMR study.

Authors:  Bhupendar Tayal; Maan Malahfji; John M Buergler; Dipan J Shah; Sherif F Nagueh
Journal:  PLoS One       Date:  2021-02-10       Impact factor: 3.240

10.  The Indices of Cardiovascular Magnetic Resonance Derived Atrial Dynamics May Improve the Contemporary Risk Stratification Algorithms in Children with Hypertrophic Cardiomyopathy.

Authors:  Lidia Ziółkowska; Łukasz Mazurkiewicz; Joanna Petryka; Monika Kowalczyk-Domagała; Agnieszka Boruc; Katarzyna Bieganowska; Elżbieta Ciara; Dorota Piekutowska-Abramczuk; Mateusz Śpiewak; Jolanta Miśko; Magdalena Marczak; Grażyna Brzezińska-Rajszys
Journal:  J Clin Med       Date:  2021-02-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.